RxDoctor Payments Data

Veronica Constantine, OD

Optometrist · Moon Township, PANPI 1710955612

Payments from drug & device makers

$3,085in general payments, 2019–2025

Across 86 payments — averaging $35.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$1K
  • Johnson & Johnson Vision Care, Inc.$392
  • Bausch & Lomb Americas Inc.$290
  • Alcon$242
  • Tarsus Pharmaceuticals, Inc.$193
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$145
  • plus $385 from 9 others

What the payments were for

  • Speaking & faculty fees$1,28542%
  • Food & beverage$1,78158%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,085 in reported general payments places this provider in the 85th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$25,792
Medicare patients
169
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast11$18,241
LumiganBimatoprost15$8,880
Brimonidine Tartrate31$3,277
Tobramycin-DexamethasoneTobramycin/Dexamethasone16$584
Timolol Maleate34$346
Dorzolamide Hcl19$258
Latanoprost34$255
ErythromycinErythromycin Base14$190
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat13$16

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$290$18,24111 claims
AbbVieLumigan$71$8,88015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Moon Township

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →